These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 6824588)
1. Immune disorders in agnogenic myeloid metaplasia: relations to myelofibrosis. Rondeau E; Solal-Celigny P; Dhermy D; Vroclans M; Brousse N; Bernard JF; Boivin P Br J Haematol; 1983 Mar; 53(3):467-75. PubMed ID: 6824588 [TBL] [Abstract][Full Text] [Related]
2. Bone marrow histopathology and biological markers as specific clues to the differential diagnosis of essential thrombocythemia, polycythemia vera and prefibrotic or fibrotic agnogenic myeloid metaplasia. Michiels JJ Hematol J; 2004; 5(2):93-102. PubMed ID: 15048058 [TBL] [Abstract][Full Text] [Related]
3. The association between autoimmunity and agnogenic myeloid metaplasia. Ben-Chetrit E; Gross DJ; Okon E; Levo Y Scand J Haematol; 1983 Nov; 31(5):410-2. PubMed ID: 6606213 [TBL] [Abstract][Full Text] [Related]
4. [Immunitary disorders during myeloid splenomegaly with myelofibrosis]. Boivin P; Hakim J; Kahn A; Bernard JF Nouv Presse Med; 1972 Apr; 1(14):960. PubMed ID: 5019303 [No Abstract] [Full Text] [Related]
5. [Serum immunological abnormalities in myeloid splenomegaly and myelosclerosis]. Boivin P Rev Roum Med Intern; 1973; 10(3):170-7. PubMed ID: 4123073 [No Abstract] [Full Text] [Related]
6. Immunoglobulin levels in polycythemia vera, erythrocytosis, secondary polycythemia and myelofibrosis. Meytes D; Shacked N; Padeh B; Czerniak P; Pinkhas J; Ramot B Isr J Med Sci; 1972 Jul; 8(7):925-31. PubMed ID: 4115562 [No Abstract] [Full Text] [Related]
7. The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates. Tefferi A; Lasho TL; Schwager SM; Steensma DP; Mesa RA; Li CY; Wadleigh M; Gary Gilliland D Br J Haematol; 2005 Nov; 131(3):320-8. PubMed ID: 16225651 [TBL] [Abstract][Full Text] [Related]
8. Presence of unfavorable cytogenetic abnormalities is the strongest predictor of poor survival in secondary myelofibrosis. Dingli D; Schwager SM; Mesa RA; Li CY; Dewald GW; Tefferi A Cancer; 2006 May; 106(9):1985-9. PubMed ID: 16568439 [TBL] [Abstract][Full Text] [Related]
9. Splenectomy in agnogenic myeloid metaplasia and postpolycythemic myeloid metaplasia. A study of 34 cases. Brenner B; Nagler A; Tatarsky I; Hashmonai M Arch Intern Med; 1988 Nov; 148(11):2501-5. PubMed ID: 3190384 [TBL] [Abstract][Full Text] [Related]
10. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia. Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157 [TBL] [Abstract][Full Text] [Related]